Epitan will be finished their clinical trials very shortly and we already know the product is working very well. Surely the current market cap is cheap for such a product. Any thoughts?
Also notice more analysts starting to look at biotechs seriously again. Reports for EPT suggest a price 2-3 times higher than current prices and thats before phase II is released.
Is this stock a buy???
phase 2 results due very soon
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.57 |
Change
-0.420(2.80%) |
Mkt cap ! $730.3M | |||
| Open | High | Low | Value | Volume |
| $15.02 | $15.20 | $14.56 | $799.8K | 54.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 304 | $14.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.63 | 1 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$14.61 |
Change
-0.420 ( 3.01 %) |
||||
| Open | High | Low | Volume | ||
| $14.78 | $14.85 | $14.57 | 4835 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| CUV (ASX) Chart |